Our results suggest that blocking the BAFF-BAFF-R axis in combination with existing therapies could potentially achieve two goals; reduce tumor burden in the periphery and eliminate the supply of more aggressive precursor CLL cells. The gene discussed is TNFSF13B; the disease is neoplasm.